Health and Healthcare

High-Premium Biotech M&A Continues (AMGN, CELG, MITI, IBB)

Thursday brought yet more merger and acquisition news in the ongoing buyout trends in the biotech sector.  Amgen Inc. (NASDAQ: AMGN) announced that it is going to acquire Micromet, Inc. (NASDAQ: MITI), a cancer drug maker that is German and American.  Celgene Corporation (NASDAQ: CELG) announced that it was going to acquire an outfit called Avila Therapeutics, a developer of cancer drugs.

The Micromet deal is valued at $11.00 per share.  This was a 33% premium to the prior close and shares closed up 32% at $10.94.  The prior 52-week range was $4.13 to $8.90.  Unfortunately for M&A arbitrage players, this deal offers no real upside in an arb-spread and it seems unlikely that a higher bid is coming based upon its share price never having gone above $11.00 today.  That buyout is on the heels of a deal signed last year where Amgen agreed to an upfront payment for a discovery and development deal.  Amgen is indicated around $69 after turning in 3% sales growth after the close.

Avila Therapeutics is a developer of covalent drugs in cancer and this $925 million buyout from Celgene is a cash and stock deal with $350 million of the total coming in cash.  This company has AVL-292 as a inhibitor now in Phase I studies.  Celgene shares are around $72.65 and are also with striking distance of a 52-week high ($75.11).

It is interesting that with two deals already having been announced in the last 24-hours that the iShares Nasdaq Biotechnology (NASDAQ: IBB) ETF was down by almost 1% at $114.71 on a day when there were two deals on the heels of another large premium acquisition this week.

JON C. OGG

Is Your Money Earning the Best Possible Rate? (Sponsor)

Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.

However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.

There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.